Company intelligence / Profile preview

Wuhan Boweid Biotechnology

Ownership: Private
Development stage: Other

Overview

Wuhan Boweid Biotechnology is a clinical-stage biopharmaceutical company focused on the development of novel recombinant oncolytic virus therapies for cancer treatment. Founded in 2010 by Dr. Cai Ligang, the company is headquartered in Wuhan, China. Its lead candidate, WeiBoEN (recombinant coxsackievirus B3 injection), is a first-in-class oncolytic virus therapy that has received IND clearance from both the US FDA and China's NMPA for the treatment of advanced non-small cell lung cancer (NSCLC). Wuhan Boweid Biotechnology maintains complete, independent intellectual property rights over its pipeline, spanning from upstream strain construction to downstream manufacturing processes.

Therapeutic areas: Oncology
Modalities: Oncolytic virus therapyBiologic
Industry: Biotech

Drug pipeline

1 asset

recombinant coxsackievirus B3

Unknown

Beyond the preview

Go deeper on Wuhan Boweid Biotechnology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Wuhan Boweid Biotechnology.